The role of EMAST-positive colorectal cancer cell in inflammatory bowel disease and finding the novel target factors.

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K16509
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Osaka University
• Principal Investigator: Munakata Koji 大阪大学, 大学院医学系研究科, 招へい教員 (70621043)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: 炎症性腸疾患 / Colitic cancer / EMAST

Outline of Final Research Achievements

To create a new therapeutic approach for colitic cancer in the context of inflammatory bowel disease, we focused on elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), a form of microsatellite instability. Since the reliability of the experimental system for detecting EMAST is the most important "foundation" of this study, we first confirmed the reliability of the experimental system using area of cancer and non-cancer. We confirmed that our detection system of EAST was function. Next, DNA was extracted from non-cancer cancer areas of colitis cancer cases. But it was difficult to stably detect EMAST using one. Because of our technical methods and of quality of DNA that were extracted from relatively recent cases.
So next approach might be that target gene candidates were selected using EMAST positive DNA from tissue of colitic cancer.

Free Research Field

Colitic cancer

Academic Significance and Societal Importance of the Research Achievements

IBDに対する内科的治療の進歩によって長期経過例が多くなり、colitic cancerの発生頻度は病脳期間により高率となる。また通常の大腸癌と異なりcolitic cancerは発生経路が異なり悪性度が高いことが知られており、colitic cancerの発生経路の解明が期待されている。今回、DNAの不安定性を示すelevated microsatellite alterations at selected tetranucleotide repeats (EMAST)に着目し、全く新しいアプローチを行うことは、学術的意義はもちろん、成果が得られた際には社会的意義は非常に大きいと考えられた。